244 related articles for article (PubMed ID: 16818626)
1. Epigenetic silencing of the PTEN gene in melanoma.
Mirmohammadsadegh A; Marini A; Nambiar S; Hassan M; Tannapfel A; Ruzicka T; Hengge UR
Cancer Res; 2006 Jul; 66(13):6546-52. PubMed ID: 16818626
[TBL] [Abstract][Full Text] [Related]
2. PTEN Methylation Dependent Sinonasal Mucosal Melanoma.
Lee SH; Roh MR; Kang B; Park KH; Kim SH; Lee SE; Rha SY
Cancer Res Treat; 2016 Apr; 48(2):853-8. PubMed ID: 25797573
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
4. Aberrant CpG island methylation of PTEN is an early event in nasopharyngeal carcinoma and a potential diagnostic biomarker.
Li J; Gong P; Lyu X; Yao K; Li X; Peng H
Oncol Rep; 2014 May; 31(5):2206-12. PubMed ID: 24604064
[TBL] [Abstract][Full Text] [Related]
5. Methylation and mutation of the inhibin‑α gene in human melanoma cells and regulation of PTEN expression and AKT/PI3K signaling by a demethylating agent.
Ko H; Ahn HJ; Kim YI
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958114
[TBL] [Abstract][Full Text] [Related]
6. Altered transcription and expression of PTEN in breast tumors: is it regulated by hypermethylation?
Shetty PJ; Pasupuleti N; Chava S; Nasaruddin K; Hasan Q
Breast Dis; 2011; 33(1):27-33. PubMed ID: 21846942
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.
Marini A; Mirmohammadsadegh A; Nambiar S; Gustrau A; Ruzicka T; Hengge UR
J Invest Dermatol; 2006 Feb; 126(2):422-31. PubMed ID: 16374457
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
9. Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival.
Roh MR; Gupta S; Park KH; Chung KY; Lauss M; Flaherty KT; Jönsson G; Rha SY; Tsao H
J Invest Dermatol; 2016 May; 136(5):1002-1011. PubMed ID: 26854490
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation status of multiple genes in uveal melanoma.
Merhavi E; Cohen Y; Avraham BC; Frenkel S; Chowers I; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4403-6. PubMed ID: 17898258
[TBL] [Abstract][Full Text] [Related]
11. Promoter methylation of the PTEN gene is a common molecular change in breast cancer.
García JM; Silva J; Peña C; Garcia V; Rodríguez R; Cruz MA; Cantos B; Provencio M; España P; Bonilla F
Genes Chromosomes Cancer; 2004 Oct; 41(2):117-24. PubMed ID: 15287024
[TBL] [Abstract][Full Text] [Related]
12. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation-induced E-cadherin silencing is correlated with the clinicopathological features of melanoma.
Venza M; Visalli M; Catalano T; Biondo C; Beninati C; Teti D; Venza I
Oncol Rep; 2016 Apr; 35(4):2451-60. PubMed ID: 26883095
[TBL] [Abstract][Full Text] [Related]
14. Loss of PTEN promotes tumor development in malignant melanoma.
Stahl JM; Cheung M; Sharma A; Trivedi NR; Shanmugam S; Robertson GP
Cancer Res; 2003 Jun; 63(11):2881-90. PubMed ID: 12782594
[TBL] [Abstract][Full Text] [Related]
15. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Soria JC; Lee HY; Lee JI; Wang L; Issa JP; Kemp BL; Liu DD; Kurie JM; Mao L; Khuri FR
Clin Cancer Res; 2002 May; 8(5):1178-84. PubMed ID: 12006535
[TBL] [Abstract][Full Text] [Related]
16. Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma.
Hallberg AR; Vorrink SU; Hudachek DR; Cramer-Morales K; Milhem MM; Cornell RA; Domann FE
Epigenetics; 2014 Dec; 9(12):1641-7. PubMed ID: 25625848
[TBL] [Abstract][Full Text] [Related]
17. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas.
Nobeyama Y; Okochi-Takada E; Furuta J; Miyagi Y; Kikuchi K; Yamamoto A; Nakanishi Y; Nakagawa H; Ushijima T
Int J Cancer; 2007 Jul; 121(2):301-7. PubMed ID: 17372906
[TBL] [Abstract][Full Text] [Related]
18. A study on promoter methylation of PTEN in sporadic breast cancer patients from North India.
Siddiqui S; Akhter N; Deo SV; Shukla NK; Husain SA
Breast Cancer; 2016 Nov; 23(6):922-931. PubMed ID: 26754093
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.
van der Velden PA; Metzelaar-Blok JA; Bergman W; Monique H; Hurks H; Frants RR; Gruis NA; Jager MJ
Cancer Res; 2001 Jul; 61(13):5303-6. PubMed ID: 11431374
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation profiling of 30 genes in human malignant melanoma.
Furuta J; Umebayashi Y; Miyamoto K; Kikuchi K; Otsuka F; Sugimura T; Ushijima T
Cancer Sci; 2004 Dec; 95(12):962-8. PubMed ID: 15596045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
